27F0 Stock Overview A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
KALA BIO, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for KALA BIO Historical stock prices Current Share Price US$5.60 52 Week High US$8.19 52 Week Low US$4.22 Beta -2.14 1 Month Change -10.04% 3 Month Change 12.54% 1 Year Change -9.60% 3 Year Change -90.55% 5 Year Change -96.61% Change since IPO -99.31%
Recent News & Updates
New minor risk - Share price stability Nov 13
New major risk - Shareholder dilution Jul 08 KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP Jun 29
KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP Jun 28
KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP Jun 27
KALA BIO, Inc., Annual General Meeting, Jun 11, 2024 May 01 See more updates
New minor risk - Share price stability Nov 13
New major risk - Shareholder dilution Jul 08 KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP Jun 29
KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP Jun 28
KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP Jun 27
KALA BIO, Inc., Annual General Meeting, Jun 11, 2024 May 01 KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP Mar 26
KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding Dec 23
New minor risk - Share price stability Oct 03
New major risk - Revenue size Aug 07
First half 2023 earnings released: US$11.35 loss per share (vs US$41.26 loss in 1H 2022) Aug 06
Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023 May 12
First quarter 2023 earnings released: US$6.99 loss per share (vs US$22.37 loss in 1Q 2022) May 09
Full year 2022 earnings released: US$29.48 loss per share (vs US$109 loss in FY 2021) Mar 04 Kala Pharmaceuticals, Inc. announced that it has received $30.999475 million in funding from Baker Bros. Advisors LP Dec 29
Kala Pharmaceuticals, Inc. Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED Dec 28
Kala Pharmaceuticals Receives Non-Compliance Notice From Nasdaq Dec 12 Kala Pharmaceuticals, Inc. announced that it expects to receive $30.999475 million in funding from Baker Bros. Advisors LP Nov 29
Third quarter 2022 earnings released: EPS: US$19.40 (vs US$21.62 loss in 3Q 2021) Nov 09
Kala Pharmaceuticals, Inc. Announces Appointment of Marjan Farid to Its Board of Directors Nov 02
Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.56 loss in 2Q 2021) Aug 12
Kala Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 09
Kala Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Jul 11
Alcon Pharmaceuticals Ltd and Alcon Vision, LLC completed the acquisition of EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA). Jul 09
Kala Pharmaceuticals Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market May 29
Alcon Inc. (SWX:ALC) entered into a agreement to acquire EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $385 million. May 24 Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million. May 23
First quarter 2022 earnings released: US$0.45 loss per share (vs US$0.49 loss in 1Q 2021) May 17 Kala Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022 May 10
Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting May 03
Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022 May 02
Insufficient new directors Apr 27
Full year 2021 earnings released: US$2.19 loss per share (vs US$1.99 loss in FY 2020) Mar 30
Insufficient new directors Dec 06
Third quarter 2021 earnings released: US$0.43 loss per share (vs US$0.50 loss in 3Q 2020) Nov 16
Insufficient new directors Sep 14
No longer forecast to breakeven Aug 07
Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.42 loss in 2Q 2020) Aug 06
Insufficient new directors Aug 04
Insufficient new directors Aug 01
Insufficient new directors Jul 29
First quarter 2021 earnings released: US$0.49 loss per share (vs US$0.54 loss in 1Q 2020) May 07
Kala Pharmaceuticals Announces Preferred Position for Eysuvis™ on Cigna Mar 17
Revenue misses expectations Feb 28
Full year 2020 earnings released: US$1.99 loss per share (vs US$2.76 loss in FY 2019) Feb 28
Kala Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021 Feb 19
Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts Feb 18
New 90-day high: €6.75 Jan 28
Kala Pharmaceuticals, Inc. Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline Jan 09
New 90-day low: €5.65 Dec 29
Kala Pharmaceuticals, Inc. Provides Update on Launch Plans for EYSUVISTM for the Treatment of Dry Eye Disease Nov 18
Revenue beats expectations Nov 07
Third quarter 2020 earnings released: US$0.50 loss per share Nov 07
Kala Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 30
Kala Pharmaceuticals Announces FDA Approval of EYSUVIS™ for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease Oct 29
New 90-day low: €5.80 Oct 29
New 90-day low - €7.15 Aug 29
Kala Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 06, 2020 Jul 31
New 90-day low - €8.55 Jul 24 Shareholder Returns 27F0 DE Biotechs DE Market 7D -3.2% -3.5% -2.0% 1Y -9.6% -14.7% 6.9%
See full shareholder returns
Return vs Market: 27F0 underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is 27F0's price volatile compared to industry and market? 27F0 volatility 27F0 Average Weekly Movement 8.9% Biotechs Industry Average Movement 6.8% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 27F0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 27F0's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company’s product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases.
Show more KALA BIO, Inc. Fundamentals Summary How do KALA BIO's earnings and revenue compare to its market cap? 27F0 fundamental statistics Market cap €26.22m Earnings (TTM ) -€37.44m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 27F0 income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$38.96m Earnings -US$38.96m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -8.45 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio 512.3%
How did 27F0 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 00:02 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources KALA BIO, Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Tazeen Ahmad BofA Global Research Yi Chen H.C. Wainwright & Co. Raghuram Selvaraju H.C. Wainwright & Co.
Show 7 more analysts 
